15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Enanta Pharmaceuticals Inc, 5 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $12.00 to $28.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $19.25 sits 43% above the current $13.49. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.48 next quarter toward $-2.53 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Strong Buy
Strong Buy00%
Buy5100%
Hold00%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Enanta Pharmaceuticals Inc.
As of Sep, 3 of 3 firms rate ENTA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ENTA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.48
Range $-0.48 – $-0.48 · 1 analysts · +14% YoY
Next period, 1 analysts expect Enanta Pharmaceuticals Inc to earn $-0.48 a share (range $-0.48 – $-0.48), versus $-0.42 a year earlier. Full-year consensus is $-2.36, growing to $-2.53 the year after.
REVENUE · NEXT QUARTER
$14.5M
Range $14.5M – $14.5M · 1 analysts · -22% YoY
Revenue is expected to reach $14.5M (range $14.5M – $14.5M), -22.1% year-over-year. Full-year consensus is $63.5M, rising to $62.5M next year.
Top analysts covering Enanta Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ENTA.
#1
Anupam Rama
JP Morgan · Rank #75
Buy
$17.00+26.0% to target
Overall win rate
51%
+ Follow
#2
Roy Buchanan
JMP Securities · Rank #114
Buy
$25.00+85.3% to target
Overall win rate
49%
+ Follow
#3
Ed Arce
HC Wainwright & Co. · Rank #132
Buy
$18.00+33.4% to target
Overall win rate
44%
+ Follow
#4
BF
Brandon Folkes
HC Wainwright & Co. · Rank #221
Buy
$20.00+48.3% to target
Overall win rate
42%
+ Follow
#5
Roanna Ruiz
SVB Leerink · Rank #388
Hold
$9.00-33.3% to target
Overall win rate
31%
+ Follow
ENTA stock forecast FAQ
What is ENTA's average 12-month price target?+
The 4 analysts with a live target average $19.25 for Enanta Pharmaceuticals Inc over the next 12 months, ranging from a $28.00 high to a $12.00 low.
Is ENTA stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 5 analyst ratings, 5 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ENTA?+
The Street-high target is $28.00 (WestPark Capital), and the Street-low is $12.00 (Evercore ISI Group). The average of all 4 active targets is $19.25.
How many Wall Street analysts cover ENTA?+
5 analysts have an active rating on Enanta Pharmaceuticals Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering ENTA?+
Among analysts who currently cover ENTA, Anupam Rama of JP Morgan has the strongest overall Quantellect track record (Rank #75). Their current call is Buy with a $17.00 target.
What is Enanta Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.48 per share (range $-0.48 – $-0.48) across 1 analysts. Full-year EPS is projected at $-2.36, rising to $-2.53 the following year.
How much revenue is Enanta Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $14.5M (range $14.5M – $14.5M). Full-year revenue is projected at $63.5M, growing to $62.5M next year.
Have analysts been upgrading or downgrading ENTA lately?+
As of Sep, 3 of 3 firms rate ENTA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ENTA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
